NeuroStar TMS Therapy System: Utilization and Outcomes

NCT ID: NCT01114477

Last Updated: 2015-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

307 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-03-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The major objective of this observational study is to describe clinical outcomes of patients receiving treatment with the NeuroStar TMS Therapy system in routine clinical practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major Depressive Disorder

Exclusion Criteria

* Contraindications to treatment with TMS
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Neuronetics

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark Demitrack, MD

Role: STUDY_DIRECTOR

Neuronetics, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lee Ann Kelley, M.D., PC

Phoenix, Arizona, United States

Site Status

Bay Psychiatric Associates

Berkeley, California, United States

Site Status

TMS Center of Beverly Hills

Beverly Hills, California, United States

Site Status

Clinical Training & Research Institute

Burlingame, California, United States

Site Status

Sacramento TMS

El Dorado Hills, California, United States

Site Status

Martha Koo, MD

Hermosa Beach, California, United States

Site Status

Orange County TMS Center

Laguna Hills, California, United States

Site Status

Depression Research Center and Clinic-Semel Institute for Neuroscience & Human Behavior at UCLA

Los Angeles, California, United States

Site Status

Kevin Kinback, MD

Mission Viejo, California, United States

Site Status

Todd Hutton, MD & Associates

Pasadena, California, United States

Site Status

The Botkiss Center for TMS Therapy

San Diego, California, United States

Site Status

Stanford Hospital and Clinics

Stanford, California, United States

Site Status

Arjun Reyes, MD

Woodland Hills, California, United States

Site Status

Hartford Hospital

Hartford, Connecticut, United States

Site Status

Comprehensive Psychiatric Care

Norwich, Connecticut, United States

Site Status

Christiana Care Health Services

Wilmington, Delaware, United States

Site Status

Health Sciences America, LLC

Boca Raton, Florida, United States

Site Status

Curtis Cassidy, MD

Lakeland, Florida, United States

Site Status

Brian Teliho, MD

Atlanta, Georgia, United States

Site Status

Carl M. Wahlstrom, Jr. MD Limited

Chicago, Illinois, United States

Site Status

Northwestern Medical Faculty Foundation

Chicago, Illinois, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Brain Stimulation Chicago North Shore

Northbrook, Illinois, United States

Site Status

Behavioral Health Care Associates

Schaumburg, Illinois, United States

Site Status

University Psychiatric Foundation

Louisville, Kentucky, United States

Site Status

Integrative Psychiatry

Louisville, Kentucky, United States

Site Status

Spectrum Behavioral Health

Annapolis, Maryland, United States

Site Status

Sheppard Pratt Health System

Baltimore, Maryland, United States

Site Status

Anthony Drobnick, MD

Saint Michaels, Maryland, United States

Site Status

Newton-Wellesley Psychiatry

Newton, Massachusetts, United States

Site Status

Central Psychiatry

Las Vegas, Nevada, United States

Site Status

TMS Center of New England

Portsmouth, New Hampshire, United States

Site Status

Santa Fe TMS Therapy Center

Santa Fe, New Mexico, United States

Site Status

Dent Neurosciences Research Center, Inc.

Amherst, New York, United States

Site Status

The TMS Institute of Pennsylvania-Advanced Neuropsychiatric Solutions

West Chester, Pennsylvania, United States

Site Status

Butler Hospital

Providence, Rhode Island, United States

Site Status

W. Scott West, M.D.

Nashville, Tennessee, United States

Site Status

Texas Neuropsychiatric Institute

Amarillo, Texas, United States

Site Status

Texas TMS Center at Senior Adults Specialty Healthcare (SASH)

Austin, Texas, United States

Site Status

Houston TMS

Houston, Texas, United States

Site Status

Agape Mind Services/The Costello Clinic

Lewisville, Texas, United States

Site Status

Serenity Center for Depression, P.A.

Sugar Land, Texas, United States

Site Status

University Neuropsychiatric Institute

Salt Lake City, Utah, United States

Site Status

Center for Anxiety and Depression

Mercer Island, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Dunner DL, Aaronson ST, Sackeim HA, Janicak PG, Carpenter LL, Boyadjis T, Brock DG, Bonneh-Barkay D, Cook IA, Lanocha K, Solvason HB, Demitrack MA. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. J Clin Psychiatry. 2014 Dec;75(12):1394-401. doi: 10.4088/JCP.13m08977.

Reference Type DERIVED
PMID: 25271871 (View on PubMed)

Janicak PG, Dunner DL, Aaronson ST, Carpenter LL, Boyadjis TA, Brock DG, Cook IA, Lanocha K, Solvason HB, Bonneh-Barkay D, Demitrack MA. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. CNS Spectr. 2013 Dec;18(6):322-32. doi: 10.1017/S1092852913000357. Epub 2013 Jul 30.

Reference Type DERIVED
PMID: 23895940 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

19-50001-000

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Accelerated TMS for MDD
NCT07147218 RECRUITING NA
In-patient SCC TMS
NCT05645575 RECRUITING NA
Brief, High-dose rTMS for Depression
NCT04657432 ACTIVE_NOT_RECRUITING NA
rTMS for Depression
NCT06484413 COMPLETED